Company Overview
Boundless Bio, Inc. operates as a clinical-stage oncology company dedicated to developing interrogating extrachromosomal DNA (ecDNA) directed therapies specifically designed to treat patients with oncogene amplified cancers. The company functions within the healthcare sector and the biotechnology industry, positioning itself to leverage advanced biological mechanisms to address complex cancer subtypes that may be resistant to traditional treatments. In terms of scale, the company carries a market capitalization of $24.87M and maintains an employee count of 28, reflecting a lean operational structure typical of early-stage development entities. The combination of a relatively small market cap and the absence of reported annual revenue indicates that the company is currently in a capital-intensive research phase where value is driven by pipeline potential rather than current commercial sales.
Financial Health
The company reports a net income of $-58,197,000 and an EBITDA of $-62,301,000, while revenue figures are not available for the trailing twelve months, revealing a cost structure where significant expenditures are being incurred without corresponding current income generation. The free cash flow stands at $-31,409,000, which signifies that the company is burning through cash reserves to fund its clinical trials and operational overhead, thereby limiting immediate financial flexibility until revenue streams are established. All three margin metrics—the gross margin, operating margin, and profit margin—are reported at 0.0%, indicating that the company has not yet achieved profitability or generated positive gross revenue to calculate meaningful margins. On the liability side, the company holds $107.58M in cash against $49.03M in debt, resulting in a debt-to-equity ratio of 49.70, which suggests a highly leveraged position relative to equity but one supported by substantial cash liquidity. The current ratio of 8.74 demonstrates a very strong short-term liquidity position, implying the company possesses ample current assets to cover its short-term obligations without immediate distress. Return on equity is -46.7% and return on assets is -21.9%, metrics that reveal management is currently utilizing shareholder capital and assets to generate negative returns as the company invests heavily in its development pipeline.
Valuation Assessment
The trailing twelve-month P/E ratio is not available due to the lack of earnings, while the forward P/E is listed as -0.86, a negative figure that implies earnings are projected to remain negative in the near term rather than indicating a standard earnings trajectory. The price-to-book ratio is 0.25, suggesting the market values the company at a fraction of its net asset value, which often occurs in biotechnology firms with significant intangible assets and R&D investments that are not fully captured on the balance sheet. Although the price-to-sales ratio is not available for calculation, the EV/EBITDA multiple is 0.54, providing an alternative valuation lens that compares enterprise value to earnings before interest, taxes, depreciation, and amortization despite the underlying losses. The stock has traded between a 52-week high of $1.78 and a 52-week low of $0.96, and without a specific current price to calculate a precise percentage deviation, the asset is understood to trade within this defined historical volatility range. The beta value is not available, preventing a direct comparison of the stock's price volatility relative to the broader market movements.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not available, reflecting the company's stage of development where historical growth rates are not yet applicable for analysis. Because the company has not generated positive earnings, it does not pay dividends; consequently, the dividend yield is not available and the payout ratio is 0.0%. The company reinvests all available capital and operational earnings into its clinical pipeline and research activities rather than distributing cash to shareholders. The overall growth and income profile is characterized by a lack of historical growth data and a complete absence of dividend income, relying entirely on future clinical success to transition from a non-dividend payer to a revenue-generating entity.